This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Osiris CEO: Our Stem Cell Drug With Zero Sales Is Widely Used

COLUMBIA, Md. ( TheStreet) -- Osiris Therapeutics (OSIR - Get Report) CEO Randy Mills, speaking to investors on his company's first-quarter conference call Tuesday morning about Prochymal, a stem cell therapy for graft-versus-host disease:

We have made Prochymal by far -- by far -- the most widely used stem cell drug in the world. So, we regularly and constantly treat patients now on four different continents and are literally treating a patient with Prochymal anywhere around the world at any given time of the day.

Prochymal is the most widely used stem cell drug in the world? Really?

Mills has a different definition of "widely used" than most investors.

Prochymal sales since the stem cell drug was approved in Canada in May 2012 and New Zealand in June 2012: $0.

Reimbursement process in Canada: Incomplete.

Update on Prochymal confirmatory trial, which is required as part of Canadian approval: Incomplete.

Status of long-delayed plans to submit Prochymal for U.S. approval: On permanent hold.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
OSIR $6.15 -3.80%
AAPL $94.34 0.34%
FB $100.27 -3.70%
GOOG $673.50 -1.50%
TSLA $150.07 -7.70%


Chart of I:DJI
DOW 15,882.55 -322.42 -1.99%
S&P 500 1,836.68 -43.37 -2.31%
NASDAQ 4,242.0150 -121.1290 -2.78%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs